Vivani Medical, Inc.
Vivani Medical, Inc.
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Financial Statements
Values in Millions ($) | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Financial statements beyond 3 years are for subscribers only. Unlock 17+ years of income statements, balance sheets, and cash flow statements Start 7-day free trial |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets | |||||||||||||||||
Cash And Cash Equivalents At Carrying Value | 20 | 20 | 16 | 3 | 7 | 13 | 18 | 20 | 25 | 30 | 21 | 25 | |||||
Assets Current | |||||||||||||||||
Assets Current | 22 | 22 | 18 | 4 | 9 | 15 | 20 | 21 | 26 | 32 | 23 | 31 | |||||
Receivables Net Current | - | 0 | - | - | - | - | - | - | - | - | - | - | |||||
Prepaid Expense And Other Assets Current | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 1 | 2 | 2 | 6 | |||||
Property Plant And Equipment Net | 3 | 3 | 3 | 3 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | |||||
Operating Lease Right Of Use Asset | 16 | 17 | 17 | 17 | 17 | 18 | 18 | 18 | 19 | 19 | 20 | 20 | |||||
Restricted Cash And Cash Equivalents Noncurrent | - | - | - | - | - | - | 1 | - | - | - | 1 | - | |||||
Restricted Cash Noncurrent | - | - | 1 | - | - | - | 1 | - | - | - | - | - | |||||
Other Assets Noncurrent | 1 | 1 | - | 1 | 1 | 1 | - | 1 | 1 | 1 | 1 | 1 | |||||
Assets | 42 | 42 | 39 | 25 | 29 | 35 | 42 | 43 | 48 | 54 | 46 | 53 | |||||
Liabilities And Stockhold… | |||||||||||||||||
Accounts Payable Current | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | |||||
Accrued Liabilities Current | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | |||||
Liabilities Current | |||||||||||||||||
Liabilities Current | 7 | 7 | 7 | 7 | 7 | 6 | 6 | 6 | 6 | 6 | 6 | 7 | |||||
Litigation Reserve Current | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | |||||
Employee Related Liabilities Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | |||||
Operating Lease Liability Current | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | |||||
Operating Lease Liability Noncurrent | 16 | 16 | 17 | 17 | 17 | 18 | 18 | 18 | 19 | 19 | 19 | 20 | |||||
Liabilities | 23 | 23 | 24 | 24 | 24 | 24 | 24 | 25 | 24 | 25 | 25 | 27 | |||||
Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Stockholders Equity | |||||||||||||||||
Stockholders Equity | 19 | 19 | 16 | 1 | 5 | 12 | 18 | 18 | 24 | 29 | 21 | 26 | |||||
Additional Paid In Capital | 181 | 174 | 164 | 143 | 140 | 140 | 139 | 134 | 134 | 133 | 119 | 119 | |||||
Accumulated Other Comprehensive Income Loss Net Of… | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Retained Earnings Accumulated Deficit | -162 | -155 | -149 | -142 | -135 | -128 | -122 | -116 | -110 | -104 | -98 | -92 | |||||
Liabilities And Stockholders Equity | 42 | 42 | 39 | 25 | 29 | 35 | 42 | 43 | 48 | 54 | 46 | 53 | |||||
Preferred Stock Par Or Stated Value Per Share | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Common Stock No Par Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Preferred Stock Shares Authorized | - | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | |||||
Preferred Stock Shares Outstanding | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Common Stock Shares Authorized | 300 | 300 | 300 | 300 | 300 | 300 | 300 | 300 | 300 | 300 | 300 | 300 | |||||
Common Stock Shares Issued | 89 | 85 | 76 | 62 | 59 | 59 | 59 | 55 | 55 | 55 | 51 | 51 | |||||
Shares Outstanding | 89 | 85 | 76 | 62 | 59 | 59 | 59 | 55 | 55 | 55 | 51 | 51 | |||||
Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables
Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables
Custom Table
Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals
Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals
Interactive Financial Visualizations
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Earnings Market Reaction
| Fiscal Year | Q1 1 Month | Q1 2 Month | Q1 3 Month | Q2 1 Month | Q2 2 Month | Q2 3 Month | Q3 1 Month | Q3 2 Month | Q3 3 Month | Q4 1 Month | Q4 2 Month | Q4 3 Month |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 1.72% | 8.62% | 10.34% | - | - | - | - | - | - | - | - | - |
| 2025 | 9.52% | 20.00% | 26.67% | 2.38% | 11.11% | 27.78% | 3.32% | -6.27% | 2.58% | 24.07% | 8.33% | 1.85% |
| 2024 | -12.70% | -33.51% | -35.14% | 0.86% | 1.72% | 11.21% | -4.32% | -7.91% | -14.39% | 0.00% | 7.62% | 20.00% |
| 2023 | - | - | - | -21.31% | -15.57% | -12.30% | -8.24% | 2.94% | 0.98% | -9.57% | 6.12% | -14.89% |
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial | ||||||||||||
Subscribe to unlock 17+ years of financial data and 90+ calculated metrics
Subscribe to unlock 17+ years of data and 90+ calculated metrics
Performance and Valuation Metrics
Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.
Metrics | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Metric history beyond 3 years is for subscribers only. Unlock 17+ years of history across 90+ calculated metrics Start 7-day free trial |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Liquidity Ratios | |||||||||||||||||
| Current Ratio | 3.25 | 3.18 | 2.71 | 0.61 | 1.30 | 2.40 | 3.41 | 3.41 | 4.55 | 5.13 | 4.03 | 4.13 | |||||
| Quick Ratio | 3.09 | 3.02 | 2.56 | 0.48 | 1.09 | 2.13 | 3.11 | 3.13 | 4.31 | 4.83 | 3.61 | 3.34 | |||||
| Working Capital | 14.98M | 14.77M | 11.30M | -2.66M | 2.00M | 8.65M | 14.46M | 15.13M | 20.55M | 25.36M | 17.34M | 23.25M | |||||
Leverage & Debt | |||||||||||||||||
| Debt to Equity | 1.20 | 1.22 | 1.50 | 18.13 | 4.89 | 2.05 | 1.36 | 1.34 | 1.02 | 0.87 | 1.21 | 1.03 | |||||
| Debt Ratio | 0.54 | 0.55 | 0.60 | 0.95 | 0.83 | 0.67 | 0.58 | 0.57 | 0.51 | 0.47 | 0.55 | 0.51 | |||||
Efficiency & Turnover | |||||||||||||||||
| Asset Turnover TTM | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Receivables Turnover TTM | - | 0.00 | - | - | - | - | - | - | - | - | - | - | |||||
Per Share Metrics | |||||||||||||||||
| Diluted EPS TTM | -0.30 | -0.33 | -0.43 | -0.44 | -0.43 | -0.40 | -0.43 | -0.42 | -0.44 | -0.49 | -0.50 | -0.53 | |||||
| Free Cash Flow Per Share TTM | -0.30 | -0.33 | -0.41 | -0.41 | -0.39 | -0.37 | -0.39 | -0.35 | -0.39 | -0.43 | -0.48 | -0.50 | |||||
| Dividend Per Share TTM | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
Growth Metrics | |||||||||||||||||
| Net Revenue Growth (1Y) | - | - | - | - | - | - | - | - | - | - | -100.00% | -100.00% | |||||
| Net Income Growth (1Y) | 3.04% | 14.06% | 13.30% | 10.93% | 5.51% | -6.40% | -8.44% | -12.82% | 29.39% | 55.83% | 84.69% | 150.36% | |||||
| EPS Growth (1Y) | -29.91% | -16.87% | -0.16% | 2.64% | -2.01% | -17.52% | -15.32% | -19.78% | 19.45% | 51.51% | 84.27% | 86.97% | |||||
Valuation Metrics | |||||||||||||||||
| P/E TTM | -4.10 | -3.00 | -2.88 | -3.23 | -2.99 | -2.62 | -2.72 | -2.76 | -2.86 | -3.81 | -2.02 | -1.93 | |||||
| P/B TTM | 5.69 | 4.26 | 4.88 | 64.32 | 15.57 | 5.35 | 3.62 | 3.53 | 2.91 | 3.36 | 2.50 | 1.98 | |||||
| Market Cap | 107.99M | 81.27M | 76.74M | 84.19M | 76.42M | 62.20M | 63.78M | 64.64M | 69.33M | 96.57M | 51.87M | 51.85M | |||||
| Enterprise Value | 88.10M | 61.52M | 60.51M | 81.56M | 69.63M | 49.19M | 44.09M | 44.99M | 44.41M | 66.93M | 29.88M | 27.03M | |||||
Calculated Values | |||||||||||||||||
| Free Cash Flow TTM | -26.50M | -26.52M | -25.49M | -24.61M | -23.14M | -21.82M | -21.34M | -19.46M | -21.52M | -22.28M | -24.59M | -25.65M | |||||
| Net Debt | -19.89M | -19.75M | -16.23M | -2.63M | -6.79M | -13.01M | -19.69M | -19.65M | -24.92M | -29.65M | -21.99M | -24.82M | |||||
Per-Share and Margin | |||||||||||||||||
| EPS TTM | |||||||||||||||||
| Adjusted EPS TTM | |||||||||||||||||
| Cash Flow Per Share TTM | |||||||||||||||||
| Pretax Margin TTM | |||||||||||||||||
| Stock Comp to Revenue TTM | |||||||||||||||||
Turnover Ratios and Averages | |||||||||||||||||
| Average Assets | |||||||||||||||||
| Average Equity | |||||||||||||||||
| Average Inventory | |||||||||||||||||
| Average Receivables | |||||||||||||||||
| Average Accounts Payables | |||||||||||||||||
| Inventory Turnover TTM | |||||||||||||||||
| Payables Turnover TTM | |||||||||||||||||
| Days Inventory Outstanding TTM | |||||||||||||||||
| Days Payables Outstanding TTM | |||||||||||||||||
| Cash Conversion Cycle TTM | |||||||||||||||||
| Working Capital to Revenue | |||||||||||||||||
| Deferred Revenue to Revenue | |||||||||||||||||
Growth Rates | |||||||||||||||||
| Total Assets Growth (1Y) | |||||||||||||||||
| Total Assets Growth (3Y) | |||||||||||||||||
| Total Assets Growth (5Y) | |||||||||||||||||
| Dividends Paid Growth (1Y) | |||||||||||||||||
| Dividends Paid Growth (3Y) | |||||||||||||||||
| Dividends Paid Growth (5Y) | |||||||||||||||||
| EPS Growth (3Y) | |||||||||||||||||
| EPS Growth (5Y) | |||||||||||||||||
| Net Income Growth (3Y) | |||||||||||||||||
| Net Income Growth (5Y) | |||||||||||||||||
| Net Profit Margin Growth (1Y) | |||||||||||||||||
| Net Profit Margin Growth (3Y) | |||||||||||||||||
| Net Profit Margin Growth (5Y) | |||||||||||||||||
| Net Revenue Growth (3Y) | |||||||||||||||||
| Net Revenue Growth (5Y) | |||||||||||||||||
| Deferred Revenue Growth (1Y) | |||||||||||||||||
| Retained Earnings Growth (1Y) | |||||||||||||||||
Credit, Liquidity, Returns, Payout | |||||||||||||||||
| Cash Ratio | |||||||||||||||||
| Net Working Capital | |||||||||||||||||
| Debt to EBITDA TTM | |||||||||||||||||
| Net Debt to EBITDA TTM | |||||||||||||||||
| Net Debt to Equity | |||||||||||||||||
| Altman A | |||||||||||||||||
| Altman B | |||||||||||||||||
| Altman C | |||||||||||||||||
| Altman D | |||||||||||||||||
| Altman E | |||||||||||||||||
| Altman Z-Score | |||||||||||||||||
| ROA TTM | |||||||||||||||||
| ROE TTM | |||||||||||||||||
| NOPAT TTM | |||||||||||||||||
| ROIC TTM | |||||||||||||||||
| Effective Tax Rate TTM | |||||||||||||||||
| Payout Ratio TTM | |||||||||||||||||
| Dilution Ratio | |||||||||||||||||
| Retained Earnings to Equity | |||||||||||||||||
| Treasury Stock to Equity | |||||||||||||||||
| Treasury Stock Change (1Y) | |||||||||||||||||
| Accrued to Current Liabilities | |||||||||||||||||
| NCAV | |||||||||||||||||
| NCAV Per Share TTM | |||||||||||||||||
Valuation Ratios | |||||||||||||||||
| P/CF TTM | |||||||||||||||||
| PEG Ratio | |||||||||||||||||
| Dividend Yield TTM | |||||||||||||||||
| Free Cash Flow Yield TTM | |||||||||||||||||
| EV EBITDA TTM | |||||||||||||||||
| EV EBIT TTM | |||||||||||||||||
| EV Revenue TTM | |||||||||||||||||
| EV FCF TTM | |||||||||||||||||
| Stock Compensation TTM | |||||||||||||||||
| Adjusted Net Income TTM | |||||||||||||||||
| Billings TTM | |||||||||||||||||
| Total Debt | |||||||||||||||||
| Invested Capital | |||||||||||||||||
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Insider Transactions
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Institutional Ownership
Vivani Medical, Inc. (VANI) — SEC Financial Statements & Analysis
Vivani Medical, Inc. (VANI) is a electromedical & electrotherapeutic apparatus company, incorporated in DE. Vivani Medical, Inc. trades on Nasdaq as: VANI. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), Vivani Medical, Inc. reported a -100.00% year-over-year revenue growth, a Debt-to-Equity ratio of 1.20x, a Price-to-Book (P/B) ratio of 5.69x (TTM), at a market cap of $107.99M. Figures below are sourced from SEC EDGAR, as-filed.
- Net Revenue TTM Growth 1Y
- -100.00%
- Debt To Equity
- 1.20x
- P/B TTM
- 5.69x
- Market Cap
- $107.99M
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Vivani Medical, Inc. in?
Vivani Medical, Inc. (VANI) operates in the Electromedical & Electrotherapeutic Apparatus industry.
What is VANI's market cap?
Vivani Medical, Inc. (VANI) has a market capitalization of $107.99M as of 2026-06-30.
What exchange does VANI trade on?
Vivani Medical, Inc. (VANI) trades on the Nasdaq.
Where is Vivani Medical, Inc. incorporated?
Vivani Medical, Inc. is incorporated in DE.